APA (7th ed.) Citation

BL, O. S., PT, S., JN, H., C, L., MD, M., I, G., . . . K, M. (2024). SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: A phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial. The Lancet. Microbe, 5(6), e581. https://doi.org/10.1016/S2666-5247(23)00410-X

Chicago Style (17th ed.) Citation

BL, Ober Shepherd, et al. "SARS-CoV-2 Recombinant Spike Ferritin Nanoparticle Vaccine Adjuvanted with Army Liposome Formulation Containing Monophosphoryl Lipid A and QS-21: A Phase 1, Randomised, Double-blind, Placebo-controlled, First-in-human Clinical Trial." The Lancet. Microbe 5, no. 6 (2024): e581. https://doi.org/10.1016/S2666-5247(23)00410-X.

MLA (9th ed.) Citation

BL, Ober Shepherd, et al. "SARS-CoV-2 Recombinant Spike Ferritin Nanoparticle Vaccine Adjuvanted with Army Liposome Formulation Containing Monophosphoryl Lipid A and QS-21: A Phase 1, Randomised, Double-blind, Placebo-controlled, First-in-human Clinical Trial." The Lancet. Microbe, vol. 5, no. 6, 2024, p. e581, https://doi.org/10.1016/S2666-5247(23)00410-X.